Radioligand + Radiation Therapy for Prostate Cancer

This trial explores a new method to treat prostate cancer that has returned after surgery. It combines two treatments: a targeted radioactive drug, Lutetium Lu 177 PSMA-10.1, which directly attacks cancer cells, and radiation therapy, which uses high-energy rays to kill cancer cells. The trial aims to assess the safety of this combination and determine the optimal dose. Men who have undergone prostate surgery and now experience rising PSA levels, indicating cancer recurrence, might consider participating. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new therapy.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that 177Lu-rhPSMA-10.1, a type of targeted radiation therapy, is generally well-tolerated. In studies, this treatment produced promising results. Many patients experienced a significant drop in their prostate-specific antigen (PSA) levels, which can indicate cancer activity. Importantly, most patients did not suffer severe side effects. This suggests that 177Lu-rhPSMA-10.1 could be a safe option for those with recurring prostate cancer after surgery. However, as this trial is in an early stage, ongoing studies aim to confirm these findings and determine the best dose.¹²³⁴⁵

Researchers are excited about the combination of Lutetium Lu 177 PSMA-10.1 with radiation therapy for prostate cancer because it targets cancer cells more precisely. Unlike traditional treatments like chemotherapy or hormone therapy, which can affect both healthy and cancerous cells, this approach uses a radioactive compound that binds specifically to the prostate-specific membrane antigen (PSMA) found on cancer cells. This precision allows for targeted radiation delivery, potentially leading to fewer side effects and more effective tumor reduction. Additionally, the integration of advanced imaging techniques, such as PET/CT and SPECT-CT, enhances the ability to monitor treatment response, providing a clearer picture of its effectiveness.

Research has shown that 177Lu-rhPSMA-10.1, administered alongside External Beam Radiation Therapy (EBRT) in this trial, can significantly slow tumor growth. Studies have found that it targets prostate cancer cells by delivering radiation directly to the tumor, while mostly sparing healthy tissues. In patients with advanced prostate cancer, this treatment significantly lowered levels of prostate-specific antigen, a marker used to monitor the cancer. The treatment effectively balances attacking the tumor and protecting healthy organs, offering promise for controlling cancer. Overall, these findings suggest that 177Lu-rhPSMA-10.1 could be a viable option for treating prostate cancer that recurs after surgery.¹³⁶⁷⁸